Louis Yu Joins Albany Molecular Research
Albany Molecular Research Inc. (AMRI) has appointed Louis Yu senior vice president of quality and compliance, a newly created position within the company. Yu joins AMRI, a global contract research and manufacturing organisation, from Perrigo Company PLC, where he was executive vice president, global quality and compliance. Prior to that, he was vice president of quality for CV Therapeutics (now a division of Gilead Sciences), and has also held a number of senior leadership roles at Forest Laboratories, Solvay Pharmaceuticals and Par Pharmaceutical.
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.